Prelude Therapeutics Incorporated (PRLD) Stock Score, Valuation & Financial Research

Prelude Therapeutics Incorporated is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for PRLD

Prelude Therapeutics Incorporated does not currently have a complete Wall Street Score. The stored market price is USD 3.23. These figures are a research snapshot, not a buy or sell recommendation.

What Prelude Therapeutics Incorporated does

Prelude Therapeutics, Inc. is a clinical-stage precision oncology company focused on identifying and developing innovative, targeted cancer treatments for patient populations with unmet medical needs. Its pipeline includes PRT543, currently undergoing Phase 1 clinical evaluation for certain solid tumors and myeloid malignancies. Another asset, PRT811, is also in Phase 1 trials, targeting various solid tumors, notably glioblastoma multiforme. The company is additionally progressing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a powerful and highly kinome-selective CDK9 inhibitor; PRT-SCA2, which is in preclinical development for several genomically selected cancers; PRT3645, a brain-penetrant molecule that precisely and effectively targets CDK4/6; and PRT-K4, another preclinical compound for solid tumors. Founded in 2016, the firm's headquarters are located in Wilmington, Delaware.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Prelude Therapeutics is a clinical-stage precision oncology company that generates revenue primarily through research and development collaboration agreements. These agreements typically involve upfront payments, milestone payments upon the achievement of specific clinical or regulatory goals, and potential future royalties from the commercialization of licensed drug candidates.

Products and services

  • The company focuses on the discovery and development of small molecule therapies and next-generation degrader antibody conjugates (DACs) targeting cancer, including KAT6A degraders and JAK2V617F mutant selective inhibitors.

Customer types

Pharmaceutical and biotechnology companies.

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) and Contract Manufacturing Organizations (CMOs) — The company relies on third-party providers for clinical trial management, data collection, and the manufacturing of drug substances and products for clinical use. Specific supplier names are not disclosed. Source

Business strengths to evaluate

  • Proprietary precision oncology platform focused on targeted protein degradation Source

Business risks and research considerations

  • History of operating losses and expectation of continued losses Source
  • Dependence on the success of clinical-stage product candidates Source
  • Reliance on third-party manufacturers and clinical trial sites Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

PRLD financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 3.23
Market capitalization:
186.95M (currency not supplied)
Revenue:
USD 22.42M
Net income:
USD -60.49M
Free cash flow:
USD -56.37M
Cash:
USD 26.33M
Total debt:
USD 17.65M
EPS:
USD -0.79

What stands out

  • Reported year-over-year revenue growth is +84.7%.
  • Free cash flow is USD -56.37M, negative for the stored period.
  • The balance sheet shows USD 26.33M of cash versus USD 17.65M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Free cash flow is -251.4% of stored revenue. This is a simple cross-field ratio, not a verified same-period cash conversion margin; confirm reporting periods before comparison.
  • Net income equals -269.7% of stored revenue. This is an indicative ratio only; accounting periods and units should be verified in filings.
  • Cash exceeds debt by USD 8.68M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for PRLD

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • Can PRLD sustain its current revenue growth while also converting that growth into durable profit and free cash flow?
  • How long can PRLD fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • Does PRLD's balance between cash and debt leave enough flexibility if business conditions weaken?
  • What specifically needs to improve for PRLD to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of PRLD's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-15.

Research-input completeness: 82% of the scoring inputs required for this public page are currently available.

How to research PRLD

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.